Provided by Eurofins Advinus through our partner laboratory, Adgyl Lifesciences
Eurofins Advinus, in collaboration with its partner Adgyl Lifesciences, offers a comprehensive suite of in vivo pharmacology models for evaluating drug candidates targeting metabolic disorders such as diabetes, obesity, hyperlipidaemia, and atherosclerosis. These models are supported by robust metabolic assessments and biomarker profiling to deliver mechanistic and efficacy insights crucial for preclinical development.
Key In Vivo Metabolic Assessments
The platform integrates advanced metabolic profiling tools and functional testing to assess compound performance across diverse metabolic pathways.
Capabilities Offered via Adgyl Lifesciences Include
In Vivo Metabolic Profile Analysis
- Glucose Tolerance Tests (GTT): Oral (PO), Intraperitoneal (IP), and Intravenous (IV) formats
- Insulin Tolerance Test (ITT): For insulin sensitivity and glucose disposal analysis
- Mixed Meal Tolerance Test: To assess postprandial glucose response
- Oral Lipid Tolerance Test: Available for both mice and rats
- Very Low-Density Lipoprotein (VLDL) Secretion Rate: To assess hepatic lipid metabolism
- Insulin and Glucose Clamps:
- Hyperglycaemic Clamp
- Euglycemic-Hyperinsulinemic Clamp
- Indirect Calorimetry: For measuring energy expenditure and substrate utilization
- Biomarker Profiling: Multi-analyte detection to support mechanism-of-action or proof-of-concept
Animal Models for Efficacy Studies
We offer a diverse range of disease-relevant animal models tailored to replicate human metabolic syndromes:
Diet-Induced Obesity (DIO) Models
- DIO Mouse Model: Mice fed a high-fat diet (60% kcal from fat) to induce obesity and insulin resistance
Genetically Modified Models
- db/db Mice: Leptin receptor-deficient; widely used in type 2 diabetes studies
- ob/ob Mice: Leptin-deficient; ideal for obesity and insulin resistance research
- Zucker Fatty Rats: Model for obesity and hyperlipidaemia
- Zucker Diabetic Fatty (ZDF) Rats: Progressive model of type 2 diabetes
Chemically Induced Models
- STZ-Induced Type 1 Diabetic Rats: β-cell destruction via Streptozotocin
- Neonatal STZ-Induced Rats: Partial insulin deficiency model for early-onset diabetes
- STZ + DIO Mice: Combination model reflecting complex T2DM pathology with insulin resistance and β-cell dysfunction
Atherosclerosis & Lipid Profile Evaluation Models
- High Cholesterol-Fed Hamster Model: Standard for evaluating atherosclerosis and dyslipidaemia
- Serum Lipid Panel (Various Species):
- Cholesterol (Total, HDL, LDL), Triglycerides – Assessed in normal and high-fat-fed rodents
- Guinea pigs and hamsters for diet-induced lipid metabolism studies
- Glucose Levels:
- Fasted Serum Glucose
- Starch-Loaded Glucose Assessment
Additional Disease Model
- Haematopoiesis & Anaemia:
- Carboplatin-Induced Anaemia
- Iron-Deficient Diet Models
Useful for evaluating hematologic side effects and supportive interventions.
Why Choose Eurofins Advinus via Adgyl Lifesciences?
- Broad Portfolio of Validated Models: Covering obesity, diabetes, dyslipidaemia, and anaemia
- Integrated Approach: Biomarker analysis, metabolic testing, and clamp studies under one roof
- Custom Study Design: Flexibility to align with your compound’s mechanism and regulatory objectives
- Scientific Expertise: A dedicated team with deep experience in metabolic pharmacology and translational science
- End-to-End Support: From protocol design to comprehensive data interpretation
Frequently Asked Questions (FAQs)
What is the benefit of diet-induced versus genetically modified models?
Diet-induced models (e.g., DIO mice) emulate lifestyle-related metabolic syndromes, while genetically modified models (e.g., db/db, ob/ob) offer stable and reproducible disease phenotypes for gene-targeted studies.
Can I combine multiple metabolic endpoints in a single study?
Yes, we design integrated studies that combine GTT, ITT, indirect calorimetry, and biomarker analysis to provide a comprehensive view of your drug’s metabolic effects.
Why use the STZ + DIO hybrid model?
This model reflects both insulin resistance and β-cell dysfunction—ideal for testing therapies targeting complex pathways in type 2 diabetes.
How is energy expenditure measured in rodents?
We use indirect calorimetry to track oxygen consumption (VO₂), carbon dioxide production (VCO₂), and respiratory exchange ratio (RER)—offering real-time insights into metabolic rate and substrate usage.
Are your models applicable for both efficacy and mechanism-of-action studies?
Yes. All models can be adapted for screening or mechanistic research, with options for lipid and glucose profiling, biomarker analysis, and clamp-based functional assays.
Let’s solve metabolic challenges together.
From model selection to biomarker analysis, we’re here to support every step of your research. Talk to our team and explore your options.